K medicine again out of the "King fried" O drug on the stomach cancer "mountain" Hengxin Jun hundred and how?

Recently, the 2020 European Esmo Esmo was successfully held online.
a top conference in the European oncology community, ESMO attracts a large number of oncologists to share the latest research and development developments and cutting-edge trends in the industry.
in the PD-1 segment, we found that the six PD-1 monoantigens currently listed in China all appeared at the ESMO Conference, and each announced its latest clinical research progress.
Overall, on the basis of approved adaptive disorders, the current PD-1 manufacturers are actively promoting the clinical research of new adaptive disorders, and this time there are many key heavy results announced; Cancer, esophageal cancer and other adaptive diseases have also fully blossomed, PD-1 has undoubtedly entered the era of rapid pre-adaptation, combined drug use is also a big point of view, a large number of clinical trials of PD-1 combination therapy has been rolled out in the hope of seeing the efficacy of 1 plus 2.
addition to this event, what PD-1 heavyweight signals did the ESMO conference reveal? Below, we have comprehensively combed the K drug, O drug, Karelli pearl monoanti, Xindili monoanti, Ripley single resistance, for Reilly pearl single resistance 6 domestic listed PD-1 of the latest key clinical progress, welcome to discuss.
1, K medicine: Wang fried! Single-drug treatment of advanced NSCLC, nearly 1/3 of patients live five years of lung cancer is the current PD-1 manufacturers competing for the layout of the popular cancer species, from the ESMO Conference PD-1 manufacturers have disclosed clinical data, K drug in the field of lung cancer can be said to be a heavy bomb. On the last day of the
Conference, the global multi-center, randomized controlled phase III. phase III. clinical study KEYNOTE-024 five-year total survival (OS) was revealed for the first-line treatment of PD-L1 positive (TPS-50%), EGFR/ALK mutation-negative advanced non-small cell lung cancer (NSCLC).
results showed that the mid-OS in the single drug K drug and the first-line treatment group with platinum chemotherapy were 26.3 months and 13.4 months, respectively, and that up to 55% of patients in the control group crossed to the K group, with an additional 11% receiving other PD-1/PD-In the case of L1 monoantial therapy, the risk of death was reduced by 38%, and the 60-month OS rate was 31.9% and 16.3%, respectively, which meant that the five-year OS rate in the single group of K was nearly twice that of the platinum-containing chemotherapy treatment group, and nearly one third of patients survived five years.
KEYNOTE-024 Study: Five years ago, A study on KEYNOTE-024 showed for the first time that the total survival benefits and objective remission rates of patients with highly selective advanced NSCLC in immunodripated single-drug first-line therapy were significantly better than those of platinum-containing chemotherapy.
"go chemotherapy mode" once let the industry exclaim, "lung cancer treatment is going to change days."
, the further update of KEYNOTE-024 data is another example for the industry, and its "long-term survival concept" is worthy of peer thinking.
addition to this key finding, Mercadon also published data on the first-line treatment of metastasis non-small cell lung cancer, the first-line treatment of advanced NSCLC in the first-line treatment of LAG3 monoantigen-K drugs, and the first-line treatment of K-Nlapali.
, LAG3 monoantigen-K combination therapy ORR was 53%, DCR rate was as high as 81%, K-drug-nirapali combination therapy was listed 1 (PD-L1 TPS-50%) and column 2 (PD-L1 TPS 1%-1 Forty-nine percent of ORRs were 56.3 percent and 20 percent, respectively, in addition to lung cancer, and Mercadon also announced the latest advances in other areas such as liver cancer, melanoma, and head and neck cancer, such as esophageal cancer, where the combination of K-plus chemotherapy reduced the risk of death by 27 percent.
because of space constraints, only some of the key developments have been selected here, and others are not expanded.
2, O drug: two heavy III. phase study revealed to lay the first line of treatment for gastroesophageal cancer status at this year's General Assembly, O drug's biggest focus in the field of stomach cancer.
specifically, BMS also published the results of two heavy studies on the first-line treatment of gastroesophageal cancer, CheckMate 649 and ATTRACTION-4, which almost established the status of O-drug first-line treatment of gastroesophageal cancer.
CheckMate 649 was designed to assess the efficacy of O-drugs and chemotherapy vs chemotherapy for first-line treatment of advanced stomach cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.
results showed that in all patients, O-drug-chemotherapy reduced the risk of death by 20%, with the medium OS in the O-drug combination therapy group at 13.8 months and the chemotherapy control group at 11.6 months.
in patients with tumor expression PD-L1 (CPS-gt;5), the combination therapy of O drugs was more effective.
AtTRACTION-4, a survival data for CheckMate-649, was designed to assess the efficacy of O-drug-chemotherapy vs chemotherapy for first-line treatment of advanced stomach cancer/gastroesophageal junction cancer.
results showed that the O-drug-chemotherapy group significantly improved the mesopfS (10.5 vs 8.3 months, P-0.0007) compared to the chemotherapy group, reaching the main study endpoint.
BMS also reported A drug as an auxiliary therapy for phase III. Phase III clinical trial CheckMate-577 for patients with esophageal cancer and gastroesophageal connectivity cancer (GEJ).
results showed that patients treated with O-drugs had a disease-free life of 22.4 months, twice as long as 11 months in the placebo group.
CheckMate-577 clinical trial data (Photo: BMS.com) This is the first breakthrough in complementary treatment in the field of esophageal cancer and gastroesophageal cancer, and the adaptation is the second tumor that has been shown to benefit patients after melanoma.
3, Karelli Pearl Mono-Resistance: Comprehensively Promote Clinical Research on Large Cancer Species At this annual meeting, Henrika Reilly-Pearl Mono-Resistance has been selected in 10 studies, involving lung cancer, hepatocellular carcinoma, esophageal cancer, stomach and colorectal cancer, lymphoma, nasopharyngeal cancer, bile tube cancer and other fields of the latest progress, here to share its main data on lung cancer and hepatocellular cancer.
Lung Cancer: The initial efficacy and safety results of the multi-center, I./II. phase clinical study SHR-1210-II-202 queue 3 were published this time in the second-line treatment of advanced squamous NSCLC.
the group included 25 patients with non-central advanced lung squamous cancer who failed first-line treatment, treated with the Karelliju single anti-200mg q2w combined apatinib 250mg qd programme.
results show that the final considerable mitigation rate reached 36%, the medium PFS reached 6.2 months, the middle OS reached 13.3 months.
the preliminary stage, kariliju monoantigenated apatinib significantly improved the effectiveness and efficacy of second-line therapy, surpassing the efficacy of immunodone and multi-target anti-angiogenesic drugs.
hepatocellular carcinoma: Carelli's pearl monoantigen and apatini, first-line treatment ORR up to 46% This is a domestic multi-center, single-arm, Phase II clinical trial, the sample size of patients with advanced liver cancer into the group expanded to 190 cases, of which 70 first-line cases and second-line 120 cases, received Apatini 250 mg/d plus Karelli pearl single anti-200 mg qw2.
of the efficacy of several combination therapies (non-head-to-head comparisons) showed that, in terms of the main endpoints, the ORR assessed by independent imaging was 34% and 23% respectively in patients treated with first- and second-line treatments, and 46% and 25% respectively when assessed on the mRECIST standard.
first-line treatment alone, the data was close to the results of the "lunvatinistin-K drug", with ORR of 36% and 46%, respectively.
4, Xindili monoanti: clinical data in the field of lung cancer, liver cancer eye-catching ESMO Conference, Cinda Xindili single anti-a total of 6 studies (including two PHASE III. studies) selected, covering lung cancer, hepatocellular carcinoma, stomach cancer, gynecological tumors, other solid tumors, etc. , here mainly share its key data in the field of lung cancer and liver cancer.
Lung Cancer: Syndicated monoantigen and cistabin and platinum-type main endpoint ORIENT-12 is the world's first randomized, double-blind, phase III controlled clinical study for advanced squamous non-small cell lung cancer (sqNSCLC) first-line treatment.
study of 357 subjects in the group showed that the mid-level PFS assessed by the IRC was significantly longer than that of the placebo group, at 5.5 months and 4.9 months, respectively, and the medium PFS was 6.7 months and 4.9 months, respectively, reaching the preset main study endpoint.
data for the two groups were not yet mature, but the Syndicate monoantigroup benefited from the placebo group OS.
safety characteristics are consistent with previously reported ® of the Dabershu ® (Syndili monoantigen injection) and have no new safety signals.
PFS results of the ORIENT-12 study Liver cancer: Xindili monoantigen joint IBI305 first-line treatment, currently PHASE III. Phase III completed patient group study called ORIENT-32, this ESMO conference announced II In the study section, a total of 24 patients were raised and treated with 200 mg iv q3w and Beval Bead monoantigen IBI30515 mg/kg iv q3w.
results showed that the efficacy of the researchers based on RECIST v1.1 assessment, ORR of 25%, DCR of 83.3%, mOS has not yet reached, 6 months OS rate of 87.1%;
that the current ORIENT-32 study Phase III has completed the patient group, is expected to release data by the end of this year, it is worth looking forward to.
5, Ripley monoanti: The first release of 4 digestive system tumor field data At this conference, Junshi Bio for the first time published 4 gastrointestinal tumor field data, specifically related to advanced hepatoblast cell carcinoma, colorectal cancer, esophageal squamous cancer and bile tract tumors.
Advanced hepatoblast cell carcinoma: Terripri monoanti-lenphatini-GEMOX, objective remission rate of 80% This is a treatment of non-exteteable advanced intra-hepatic bile duodenal cell carcinoma (ICC) single-arm, single-center, open-label Phase II clinical trial, a total of 30 patients in the group.
the main study endpoints, ORR was 80%, 1 patient received complete remission (CR), disease control rate (DCR) was 93.3%, 6 months total survival rate was 90%, and the mid-OS had not yet been reached.
addition, 2 patients with local metastasis underwent surgical excision due to tumor stage, which also provided a new way of thinking for ICC conversion therapy.
results are thought to be probably the best ORR data for the treatment of cancer drugs in the bile system.
the same time, although the trial is a triple-four drug program, but the rate of adverse reactions above 3 is 43%, good tolerance.
ICC patient treatment response waterfall map (n-29) advanced colorectal cancer: the first PD-1 monoantigenic rhagofinib treatment, the total survival of 15.5 months of the trial called REGOORI, is currently in the Terripri single anti-combined regenerative colorectal cancer patients IB/II clinical, which is also the first study data of Terepri monoantigen in colorectal cancer.
results showed that 80mg rigoffinib and 3mg/kg tripli monoanti were determined to be the maximum to-dosage (MTD) in this study, with controlled safety, or 15.2% for assessable patients and 36.4% for disease DCR.
addition, the combination therapy benefits more from patients with reassopathic MSSS colorectal cancer without liver metastasis, with ORR up to 30%.
Recosm volume changes in patients assessed in accordance with the RECIST1.1 standard (including 30 patients with rigofinib and 3 patients with rigoffinib 120mg) in addition, Ripley monoigenic resistance also showed good tolerance and efficacy in advanced esophageal squamous cancer and advanced bile thyroid tumors.
, the imaging evaluation orR and DRR of triplio's new auxiliary treatment for esophageal squamous cancer reached 79.17% and 100%.
6, Tyrelli Pearl Monoanti: Announcing Two Key III.Phase III.Phase Clinical Studies in the Field of Lung Cancer At this ESMO Conference, one of the major points of view of The Reilly Pearl Single Resistance in Baiji Shenzhou lies in the two of the first-line treatment of NSCLC with combined chemotherapy The publication of the results of key Phase III clinical studies (RATIONALE 304 and RATIONALALE 307) makes Tyrelli Pearl monoantigen the first Chinese-developed PD-1 antibody to simultaneously conquer scaly and non-scaly NSCLC.
RATIONALE 304 is a large Phase III registered clinical study for group Chinese to evaluate the combination of terratin monoantigen and platinum chemotherapy drugs (carbapton or cisplatin), compared to the treatment of first-line IIIB or phase IV non-scaly NSCLC patients using only Python and platinum chemotherapy drugs.
RATIONALE 304 study focused on the end of the study in a total of 334 non-Lin NSCLC patients, randomly assigned to the relliju single anti-combination chemotherapy group and the simple chemotherapy group at a 2:1 scale.
results showed that the PFS of combined reilly-pearl monotherapy reached the main endpoint compared to chemotherapy alone, with the medium PFS in group A at 9.7 months, significantly higher than in group B with chemotherapy alone, while 57% of patients achieved objective remission, compared to the 37% remission rate in the chemotherapy group, the benefit patients increased by more than half, and the patient's medium remission duration (DoR) was increased by 42%.
addition, the combination chemotherapy for Reilly-Pearl monoantigen has good safety tolerance.
in the RATIONALE 307 study, 360 patients with scaly NSCLC were randomly divided into A-arms treated with rellijutin monoanti-Yerol (D1) and carbapton (D1), and Tyrelli-pearl monoantigen-yew alcohol (D1, 8 and 15).